Same Presentation, Different Code: Race and the ADHD Workup. (For HCPs)

For the HCP

Harold Robert Meyer The ADD Resource Center

Reviewed September 2, 2026 · Published September 7, 2026

What the evidence says about race and ADHD, what it asks you to do differently in the exam room, and why almost none of it adds time to your day.

Two seven-year-old boys are referred to your practice in the same week. The teacher narratives are nearly identical: out of seat, calls out, does not finish work, argues when redirected. One leaves with F90.2 and a stimulant trial. The other leaves with F91.3 and a place on a waiting list for behavioral services. Nothing in either chart explains the fork. You did not decide it on race, and you would say so honestly. The literature suggests the fork happened anyway, and that much of it was settled before either chart reached you.

That matters clinically, not only ethically. A child coded for a disruptive behavior disorder when the driver is ADHD receives an intervention that cannot reach the mechanism. He returns later, with more accumulated failure behind him and less family trust.

Key Takeaway

There is no credible evidence that ADHD is a different condition in patients of different races. There is substantial evidence that the diagnostic pathway is different, and the correction is work you are already required to do, sequenced differently.

Key Findings

Symptom presence and diagnosis diverge. Morgan and colleagues found Black children were about 70 percent less likely than otherwise similar White children to have received an ADHD diagnosis by kindergarten entry, even though teacher-reported classroom behavior showed no less frequent ADHD-related behavior.
The alternative label absorbs the difference. Using electronic health records from 50 US health systems, Shalaby and colleagues found ADHD diagnosis roughly 26 percent less prevalent in the non-Hispanic Black population than the White, and inattentive presentation 55 percent less prevalent, while conduct disorder ran 61 percent more prevalent and oppositional defiant disorder 35 percent more.
It is not White overtreatment. Coker and colleagues tested this directly: among children with neither symptoms nor diagnosis by fifth grade, medication use did not vary by race or ethnicity.
The recent rise was not shared. Katz and colleagues report diagnosis reaching 10.5 percent of US children by 2023, but rising only among Asian, White, and multiracial children and those with private insurance, while overall treatment fell from 76.9 to 70.8 percent.

The data you are handed is not neutral

The most useful finding for practice is not about clinician bias at all. It is about the informant reports that reach you before the patient does.

Kang and Harvey showed video clips of children in classrooms to Black parents, White parents, and White teachers. White teachers rated Black boys’ ADHD behaviors, and their likelihood of having ADHD, higher than Black parents did, and teachers reporting more negative racial attitudes rated Black boys higher still. The gap was widest for Black boys, though the rater groups differed on other children as well. The design cannot tell you which rater is closer to the truth, and it cannot fully separate a rater’s race from a rater’s role and setting.

What it does establish is that parent and teacher reports diverge in a race-patterned way. If you collect a Vanderbilt from home and school and read agreement as confirmation, then a wide disagreement becomes a problem to average away rather than a question to pursue. It is a question worth pursuing.

The fork between F90 and F91

Fadus and colleagues reviewed how unconscious bias operates at exactly this decision point, where the same behaviors admit a neurodevelopmental reading or a characterological one. Legha argues that oppositional defiant disorder locates the unwanted behavior in the child rather than in a neurodevelopmental difference, a trauma history, or a co-occurring mental health condition, and that the label becomes racist when applied indiscriminately to racially minoritized children.

That instruction is not new and it is not political. AAP Key Action Statement 3 already requires that every ADHD evaluation include a process to at least screen for co-occurring conditions, with oppositional defiant disorder and conduct disorder named among them. What the disparity data adds is that the differential is skipped more often for some children than for others.

“I have never met a clinician who wanted to get this wrong. I have met a great many who never saw the fork, because by the time the chart reached them, someone else had already made the choice.” – Harold Robert Meyer

Six moves, none of which lengthen the visit

Read discordant informant reports as a question, not an average. When teacher and parent diverge sharply, that is the finding. Ask what the behavior looks like at home, at a relative’s house, at church. Ninety seconds.
When a referral arrives pre-labeled, run the differential anyway. “Behavior problem,” “defiant,” and “disruptive” are not diagnoses, and you are already required to do this.
Treat school discipline history as symptom data. Suspensions and office referrals document impairment. Ask for the count. One line in your history template.
Notice which code you reached for first. If F91 came to mind before F90, ask what produced that order. A metacognitive check, not a confession.
Ask every adult patient the childhood-history question. Shalaby found adult ADHD diagnosis skews sharply toward White patients, and Alai and colleagues found non-White and Hispanic adults achieve fewer adult-ADHD quality measures around diagnosis, treatment, and prescribing. The rest will not be found unless you ask.
If you prescribe the methylphenidate patch, monitor pigmentation directly. Chemical leukoderma is a labeled risk, may persist after the drug is stopped, and can mimic vitiligo; the FDA’s 2015 safety communication reported the color loss as permanent in every case it reviewed. Depigmentation is more visible on darker skin. This is the one place in this article where skin, rather than race, is the clinical variable.

One real cost: getting a second informant report returned takes time that no reframing recovers. Everything else here changes what you read, the order you read it in, and what you ask.

What you get

The return is the one you already work for. A correctly identified patient responds to treatment that exists. A mislabeled one does not, and comes back. Yang and colleagues found that disparities in childhood ADHD treatment are driven primarily by access rather than by what happens once care has begun. These patients are reachable. Most are simply not reached.

The next step

Pull the last twenty charts in which you or a colleague assigned a disruptive behavior disorder code. Ask one question of each: was ADHD documented as considered and excluded, or was it simply never entered? That audit takes an afternoon, requires no new instrument, and will tell you more about your practice than any training module.

Synopsis

ADHD is not a different condition across racial groups, but the route to the diagnosis is. Black children are markedly less likely to be diagnosed with ADHD and markedly more likely to be coded with a disruptive behavior disorder on comparable presentations, and the recent national rise in diagnosis has not reached them. Much of the divergence is built into the informant data before the clinician sees the patient: parent and teacher ratings differ in a race-patterned way, so treating rater agreement as confirmation inherits the gap. The corrective is already in the AAP guideline. Six changes in reading, sequence, and attention are described, five of which cost no added visit time, along with one dermatologic caution specific to the methylphenidate patch.

Topic: Diagnosis & Assessment (primary); Research & Evidence; Advocacy & Rights Audience: Clinicians & prescribers; educators Keywords: ADHD diagnosis, racial disparities, differential diagnosis, oppositional defiant disorder, diagnostic bias

Bibliography

Alai, J., Callen, E. F., Clay, T., Goodman, D. W., Adler, L. A., & Faraone, S. V. (2024). Differences in primary care management of patients with adult attention deficit hyperactivity disorder (ADHD) based on race and ethnicity. Journal of Attention Disorders, 28(5), 923–935. https://doi.org/10.1177/10870547231218038

Coker, T. R., Elliott, M. N., Toomey, S. L., Schwebel, D. C., Cuccaro, P., Tortolero Emery, S., Davies, S. L., Visser, S. N., & Schuster, M. A. (2016). Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatrics, 138(3), e20160407. https://doi.org/10.1542/peds.2016-0407 · Free full text (CDC Stacks)

Fadus, M. C., Ginsburg, K. R., Sobowale, K., Halliday-Boykins, C. A., Bryant, B. E., Gray, K. M., & Squeglia, L. M. (2020). Unconscious bias and the diagnosis of disruptive behavior disorders and ADHD in African American and Hispanic youth. Academic Psychiatry, 44(1), 95–102. https://doi.org/10.1007/s40596-019-01127-6 · Free full text (PMC)

Kang, S., & Harvey, E. A. (2020). Racial differences between Black parents’ and White teachers’ perceptions of attention-deficit/hyperactivity disorder behavior. Journal of Abnormal Child Psychology, 48(5), 661–672. https://doi.org/10.1007/s10802-019-00600-y

Katz, S. M., Claussen, A. H., Alberto, C. K., Bitsko, R. H., Newsome, K., Staley, B. S., Tian, L. H., Ghandour, R. M., & Blumberg, S. J. (2026). Trends in parent-reported ADHD diagnosis and treatment among U.S. children, 2016–2023. Journal of Clinical Child & Adolescent Psychology, 55(4), 688–703. https://doi.org/10.1080/15374416.2026.2620385 · Free full text (PMC)

Legha, R. K. (2025). There are no bad kids: An antiracist approach to oppositional defiant disorder. Pediatrics, 155(2), e2024068415. https://doi.org/10.1542/peds.2024-068415

Morgan, P. L., Hillemeier, M. M., Farkas, G., & Maczuga, S. (2014). Racial/ethnic disparities in ADHD diagnosis by kindergarten entry. Journal of Child Psychology and Psychiatry, 55(8), 905–913. https://doi.org/10.1111/jcpp.12204 · Free full text (PMC)

Shalaby, N., Sengupta, S., & Williams, J. B. (2024). Large-scale analysis reveals racial disparities in the prevalence of ADHD and conduct disorders. Scientific Reports, 14, 25123. https://doi.org/10.1038/s41598-024-75954-5 · Free full text (PMC)

U.S. Food and Drug Administration. (2015, June 24). FDA drug safety communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD. https://www.fda.gov/media/92266/download

U.S. National Library of Medicine. (n.d.). Methylphenidate transdermal system: Prescribing information. DailyMed. Retrieved September 7, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb

Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528

Yang, K. G., Flores, M. W., Carson, N. J., & Cook, B. L. (2022). Racial and ethnic disparities in childhood ADHD treatment access and utilization: Results from a national study. Psychiatric Services, 73(12), 1338–1345. https://doi.org/10.1176/appi.ps.202100578 · Free full text (PMC)

Resources

About the Author

Harold Robert Meyer founded The ADD Resource Center in 1993 and has spent more than thirty years translating the lived experience of ADHD into practical guidance for individuals, families, and the clinicians and educators who work with them. He co-founded CHADD of New York in 1989 and went on to serve on CHADD National’s board and executive committee, including as Vice President of Finance. He was later elected to lead the Institute for the Advancement of ADHD Coaching. An author and international speaker, he has presented at the American Psychiatric Association Annual Meeting, CHADD national and local conferences, NYU Langone, Mount Sinai Medical Center, and Weill Cornell Medical College. Reach him at [email protected].

📚 Come back often — we add new evidence-based ADHD resources daily.

The ADD Resource Center [email protected] · +1 (646) 205-8080 · 127 West 83rd St., Unit 133, New York, NY 10024-0840 USA

X · LinkedIn · Facebook · Substack · Newsletter

✉️ Join our mailing list

Please consider the environment before printing.

Our content is educational and informational only – not medical, legal, financial, or other professional advice, nor a substitute for it, and should not be relied on as such. We strive for accuracy, but errors or omissions occur and information becomes outdated. Some content and images may be created with AI assistance and, though reviewed before publication, may contain inaccuracies. Our screening tools are not diagnostic instruments. Verify independently and consult a qualified professional before acting on anything here.

In the USA and Canada, call or text 988 anytime for free mental health and suicide prevention support, or call 911 if someone is in immediate danger. The ADD Resource Center is independent from these services and is not liable for any actions taken by you or by these services.

Under GDPR and CCPA, you may request access to, correction of, or deletion of your personal data at [email protected].

If you have ADHD or think you might:The A.D.D. Resource Center can help!